SELLAS Life Sciences Group, Inc. develops novel cancer therapeutics as a late-stage clinical biopharmaceutical company. News about SLS centers on its acute myeloid leukemia programs, including galinpepimut-S (GPS), a WT1-directed peptide immunotherapy evaluated in the REGAL Phase 3 trial, and SLS009 (tambiciclib), a selective CDK9 inhibitor studied in AML settings.
Recurring updates include clinical and preclinical data presentations, trial progress, regulatory and corporate updates, financial results, cash-position disclosures, warrant exercises, and other capital-structure developments tied to funding its oncology pipeline.
SELLAS Life Sciences Group (NASDAQ: SLS) reported Q3 2021 financial results, including a net loss of $7.1 million and no licensing revenue for the quarter. R&D expenses rose to $4.5 million, significantly up from $2.4 million in Q3 2020, driven by clinical trial activities for the Phase 3 REGAL study of galinpepimut-S (GPS) in AML. The company is also planning a Phase 2/3 study for GPS in post-BMT AML patients. As of September 30, 2021, cash equivalents stood at approximately $26.3 million, indicating ongoing financial support for its clinical initiatives.
SELLAS Life Sciences Group (NASDAQ: SLS), a biopharmaceutical company focused on cancer immunotherapies, announced that CEO Angelos Stergiou will participate in two key conferences. The first is the Laguna Biotech CEO Forum from October 10-12, 2021, in Laguna Beach, CA. The second is the A.G.P./Alliance Global Partners Biotech & Specialty Pharma Conference on October 13, 2021, which will be held virtually. SELLAS aims to advance its immunotherapeutic candidates, galinpepimut-S and nelipepimut-S, targeting various cancer indications.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced preliminary court approval for a settlement related to derivative claims against former executives of its predecessor, Galena Biopharma. The settlement includes a stipulation that mandates the company to implement specific policies concerning future commercialization of its clinical candidates. Furthermore, the company's insurer will cover up to $270,000 in legal fees. A final settlement approval hearing is scheduled for November 19, 2021.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced that CEO Angelos Stergiou will present at the 2021 Cantor Global Healthcare Conference on September 28, 2021, at 4:00 p.m. ET. The company specializes in developing innovative cancer immunotherapies, notably its lead candidate galinpepimut-S (GPS), which targets the WT1 protein in various tumors, and nelipepimut-S (NPS), aimed at early-stage breast cancer patients. For further details about the conference or to arrange meetings, interested parties can contact Cantor representatives or KCSA Strategic Communications.
SELLAS Life Sciences Group (SLS) reported significant clinical updates on Galinpepimut-S (GPS), showcasing its potential in treating malignant pleural mesothelioma and WT1+ advanced ovarian cancer. The company highlighted results from a study showing an overall survival (OS) of 48.5 months for AML patients treated with GPS. Financially, SLS recorded licensing revenue of $1.9 million for Q2 2021, with a cash position of $29.9 million as of June 30, 2021. A virtual investor symposium is scheduled for August 17, 2021, to discuss further insights on GPS and its promising clinical data.
SELLAS Life Sciences Group, a late-stage clinical biopharmaceutical company, will host a virtual investor symposium on August 17, 2021, focusing on its lead asset, galinpepimut-S (GPS). The event will detail GPS's clinical program and recent data regarding acute myeloid leukemia (AML) treatment. Notably, Dr. Yair Levy, a leading cancer researcher, will join the management team. GPS targets the WT1 protein in various tumors and has potential for treating hematologic malignancies and solid tumors.
SELLAS Life Sciences Group (NASDAQ: SLS) reported encouraging results from its Phase 1/2 clinical trial of its lead immunotherapy, galinpepimut-S (GPS), combined with pembrolizumab for advanced ovarian cancer. Notably, 100% of patients are alive, and 45.5% continue with the treatment. CD8+ T-cell responses increased by an average of +242%, indicating robust immune activation. The disease control rate was 63.6%, with a median progression-free survival of 11.8 weeks in a challenging patient cohort. These findings suggest potential for GPS as a viable therapy in difficult-to-treat cases.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced promising results from a Phase 1 trial combining its lead candidate, galinpepimut-S (GPS), with nivolumab for treating malignant pleural mesothelioma (MPM). Patients showed a median overall survival of 35.4 weeks, compared to approximately 28 weeks with standard care. The combination therapy appears to provide significant clinical benefits, especially for patients who have failed traditional treatments. SELLAS plans to provide further clinical data by the end of Q4 2021.
SELLAS Life Sciences Group (Nasdaq: SLS) announced its inclusion in the Russell Microcap Index, effective June 28, 2021. This inclusion is a significant milestone expected to enhance the company's visibility within the investment community. SELLAS, known for developing cancer immunotherapies, notably its lead candidate GPS, aims to provide treatment options for various cancer types. The Russell Microcap Index inclusion lasts for a year and is determined by market capitalization and style attributes, impacting approximately $10.6 trillion in assets.
SELLAS Life Sciences Group announced the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering galinpepimut-S (GPS) in combination with checkpoint inhibitors for treating WT1-expressing cancers. This patent extends to at least 2036 and facilitates further clinical studies for patients with advanced ovarian cancer and malignant pleural mesothelioma. CEO Angelos Stergiou emphasized the importance of this milestone for advancing their clinical pipeline and intends to release more data later this quarter.